Cite
HARVARD Citation
Kashiwagi, A. et al. (2023). Cardiometabolic risk reductions in patients with type 2 diabetes mellitus newly treated with a sodium–glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase‐4 inhibitor: A real‐world administrative database study in Japan. Journal of diabetes investigation. 14 (3), pp. 404-416. [Online].